Ways to improve the diagnostics and detection of
 cervical cancer development and recurrence risk

Abstract

th and the third most common female cancer worldwide.
 The purpose of the study was to determine risk factors and time
 to progression and recurrence in patients with cervical cancer after
 complex treatment (neoadjuvant chemotherapy + radical hysterectomy + combined radiation therapy).
 Methods: This retrospective study involved female patients with
 stage IB-IIA cervical cancer registered at Shymkent city oncological
 dispensary in 2011- 2021 (n=883). All patients underwent (n=883)
 radical hysterectomy with pelvic lymph node dissection. The patients
 were selected who underwent radiation therapy of the lower pelvis
 at a dose of ≥40 g. The age-, stage-, and tumor morphological structure-dependent survival factors and recurrence risk were analyzed
 during the research decade.
 Results: Direct correlation of the disease stage and the recurrence
 period was established. The progression was most often 5 to 6 months
 after treatment. 68.7% of progression and 63.1% of recurrences occurred in the first year and a half after the end of treatment, so this period is considered the most “dangerous” regarding the recurrence risk.
 5.3% of patients had a recurrence 19 to 24 months after treatment,
 31.5% – after more than two years.
 Conclusions: In this research, cervical cancer progressed in 74
 (10.6%) out of 883 women and recurred in 19 (3.0%). The recurrence
 was most frequent in women aged 45-50 years (28.4%) and 50-60
 years (26.3%).